What is Micron Biomedical?
Micron Biomedical, an Atlanta-based innovator, is at the forefront of dissolving microneedle-based vaccine and drug delivery technology. Originating from Georgia Tech's research labs under the guidance of Dr. Mark Prausnitz, the company has evolved into a key player in the healthtech sector. Its proprietary microneedle platform offers a minimally invasive approach to delivering therapeutics, with a particular focus on vaccine applications. The company's advancements have attracted support from a diverse range of public and private entities, including major pharmaceutical firms, global health organizations, and governmental bodies, positioning it as a leader in next-generation drug delivery solutions.
How much funding has Micron Biomedical raised?
Micron Biomedical has raised a total of $17M across 1 funding round:
Series A
$17M
Series A (2023): $17M with participation from J2 Ventures, Global Health Investment Fund, and LTS Lohmann Therapie-Systeme
Key Investors in Micron Biomedical
J2 Ventures
J2 Ventures is a venture capital firm that invests in companies within the venture capital and private equity sectors, likely focusing on early to growth-stage opportunities.
Global Health Investment Fund
Global Health Investment Fund is a non-profit organization dedicated to catalyzing the development of technologies that enhance human health globally, with a focus on improving public health and health equity.
LTS Lohmann Therapie-Systeme
LTS Lohmann Therapie-Systeme AG is a pharmaceutical technology company specializing in advanced drug delivery systems, including transdermal patches and microneedle systems, for the global healthcare industry.
What's next for Micron Biomedical?
With its recent major strategic investment, Micron Biomedical is poised for accelerated growth and further development of its groundbreaking microneedle technology. The company's trajectory suggests a focus on scaling production, expanding clinical trials, and forging new partnerships within the pharmaceutical and biotechnology industries. This capital infusion will likely enable Micron Biomedical to solidify its market position, enhance its product pipeline, and address critical global health needs through more efficient and patient-friendly drug and vaccine delivery methods. The company's ongoing innovation, supported by strategic backing, points towards a future where microneedle technology becomes a standard in therapeutic administration.
See full Micron Biomedical company page
